A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?

Antonetti, Paolo; Fargnoli, Maria Concetta; Porzio, Giampiero; Salvatore, Lisa; Filippi, Roberto; Ghidini, Michele; Nigro, Olga; Gelsomino, Fabio; Zurlo, Ina Valeria; Dell’Aquila, Emanuela; Lombardi, Pasquale; Keränen, S. Roselló; Depetris, Ilaria; Morelli, Cristina; Tursi, Michele De; Pietro, Francesca Di; Zanaletti, N.; Vitale, Pasquale; Garajová, Ingrid; Spinelli, Gian Paolo; Zoratto, Federica; Roberto, Michela; Petrillo, Angelica; Aimar, Giacomo; Cortellini, Alessio; Pensieri, Maria Vittoria; Ficorella, Corrado; Ferri, Claudio; Parisi, Alessandro

doi:10.1007/s00520-021-06652-5

Cited by 2 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cetuximab-induced skin toxicity of grades 2–4 has also been linked to a shorter OS in patients with recurrent or metastatic head and neck squamous cell carcinoma [ 26 ]. A recent study showed that a lower incidence of any grade skin reactions in the pre-emptive compared to the reactive cohort did not reduce the efficacy of antineoplastic therapy compared to the reactive in terms of ORR, median PFS, and median OS [ 27 ]. In this study, however, there was no statistically significant association between the degree of skin toxicity and OS or PFS in patients with mCRC who were administered cetuximab.…”

Section: Discussionmentioning

confidence: 99%

Skin Toxicity as a Predictor of Survival in Metastatic Colorectal Cancer Patients Treated with Anti-EGFR: Fact or Fallacy?

Chiang

Hsu

Chern

et al. 2023

Cancers

View full text Add to dashboard Cite

The primary treatment for metastatic colorectal cancer (mCRC) consists of targeted therapy and chemotherapy to improve survival. A molecular target drug with an anti-epidermal growth factor receptor (EGFR) antagonist is recommended when the RAS and BRAF genes are normal. About 50–70% of patients using anti-EGFR antagonists will experience skin reactions. Some studies have shown that severe skin reactions caused by anti-EGFR antagonists may be linked to overall survival (OS) and progression-free survival (PFS), but the results are still uncertain. These data of mCRC patients who underwent anti-EGFR therapy between October 2017 and October 2018 were analyzed retrospectively. A total of 111 patients were included in this study. The survival results showed that gender, age, body mass index, primary tumor site, and recurrence did not significantly affect OS and PFS. However, the first-line anti-EGFR inhibitor treatment was significantly associated with OS (p < 0.001) and PFS (p < 0.001). There was no significant difference in the incidence of acne between males and females in grades 1 and 2, while males have a greater risk in grades 3 and 4 than females (20.3 vs. 4.8%; p-value = 0.041). Skin toxicity was not a predictor of anti-EGFR treatment response in this investigation.

show abstract

Section: Discussionmentioning

confidence: 99%

Skin Toxicity as a Predictor of Survival in Metastatic Colorectal Cancer Patients Treated with Anti-EGFR: Fact or Fallacy?

Chiang

Hsu

Chern

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…Co ciekawe, częstsze występowanie nasilonych zmian skórnych, nychii oraz konieczność modyfikacji leczenia EGFRI stwierdzono w grupie stosującej leczenie prewencyjne w porównaniu z grupą leczoną interwencyjnie. Mimo to mniejsza całkowita liczba pacjentów leczonych prewencyjnie wymagała konsultacji dermatologicznej [21]. W praktyce profilaktyka przy zastosowaniu antybiotyku z grupy tetracyklin nie jest jednak szeroko stosowana [21].…”

Section: (Table 1)unclassified

“…Mimo to mniejsza całkowita liczba pacjentów leczonych prewencyjnie wymagała konsultacji dermatologicznej [21]. W praktyce profilaktyka przy zastosowaniu antybiotyku z grupy tetracyklin nie jest jednak szeroko stosowana [21]. W badaniu ankietowym przeprowadzonym w USA jedynie 21% pacjentów podało stosowanie antybiotyków w terapii prewencyjnej [22].…”

Section: (Table 1)unclassified

“…Interestingly, a higher incidence of severe skin lesions, paronychia, and the need to modify EGFRI treatment was found in the preventive treatment group compared to the interventional treatment group. Despite this, a smaller total number of patients treated preventively required dermatological consultation [21]. In practice, however, prophylaxis with tetracycline antibiotics is not widely used [21].…”

Section: Wnioskimentioning

confidence: 99%

“…Despite this, a smaller total number of patients treated preventively required dermatological consultation [21]. In practice, however, prophylaxis with tetracycline antibiotics is not widely used [21]. In a survey conducted in the United States of America, only 21% of patients reported the use of antibiotics in preventive therapy [22].…”

Section: Wnioskimentioning

confidence: 99%

See 2 more Smart Citations

PRIDE syndrome associated with panitumumab treatment – case report and literature review

Pałdyna¹,

Rutkowska²,

Biało-Wójcicka³

2023

View full text Add to dashboard Cite

Introduction: Epidermal growth factor receptor inhibitors, including panitumumab, are drugs with a proven effect on overal survival of patients with advanced colorectal cancer. They have a better safety profile compared to classic cytotoxic drugs, but they may have side effects resulting directly from the drug's mechanism of action. Case report: A 64-year-old man, treated palliatively with panitumumab for cancer of the sigmoido-rectal junction, was admitted to the Dermatology Department with disseminated maculopustular rash on the scalp and upper trunk. Also, layered yellowish crusts were present on the face and scalp. Edema and erythema were visible in the lateral folds of the nails of the hands and feet. The diagnosis of panitumumab -induced PRIDE syndrome (papulopustules and/or paronychia, regulatory abnormalities of hair growth, itching, and dryness due to epidermal growth factor receptor inhibitors). Laboratory tests showed hypomagnesemia, hyperglycemia and elevated glycated hemoglobin values. Doxycycline and systemic glucocorticosteroids were introduced with improvement. Conclusions: Early diagnosis of the cutaneous adverse effects oncological treatment and initiation of treatment contributes to the improvement of the quality of life of patients and the continuation of oncological therapy.

show abstract

A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?

Cited by 2 publications

References 23 publications

Skin Toxicity as a Predictor of Survival in Metastatic Colorectal Cancer Patients Treated with Anti-EGFR: Fact or Fallacy?

Skin Toxicity as a Predictor of Survival in Metastatic Colorectal Cancer Patients Treated with Anti-EGFR: Fact or Fallacy?

PRIDE syndrome associated with panitumumab treatment – case report and literature review

Contact Info

Product

Resources

About